Phase II, Open-Label, Prospective Single-Arm, Multi-Center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKI for 1L CLL Can Achieve Deep Durable Remissions (BY uMRD 10^-4) to Allow Off-Treatment Period​